CGD's new clinical trials report was featured in a Science and Development Network article.
From the Article
Joining forces would save countries money on clinical trials, and speed up drug development for neglected diseases, says a report.
Inadequate regulatory capacity in developing countries means around 90 potentially life-saving drugs, diagnostics and vaccines are lingering in the pipeline, according to a report released yesterday (31 October).
Developing countries should take a streamlined, regional approach to regulating clinical trials for drugs against neglected tropical diseases (NTDs), in which a single approval would cover multiple countries, says the report by the Center for Global Development (CGD), a think tank based in the United States.
This would speed up drug development, cut costs and save lives, it says.
Most NTDs have no effective treatments but, thanks to a large investment in recent years from philanthropic foundations, nearly 240 drug and vaccine candidates are now in development, 90 of which are waiting for late stage clinical trials. The launch of the major new open innovation platform for research on NTDs last week also promises to boost drug development.